Last reviewed · How we verify
E7337
E7337 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) signaling.
E7337 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR) signaling. Used for FGFR-altered solid tumors (in development).
At a glance
| Generic name | E7337 |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | FGFR inhibitor |
| Target | FGFR (fibroblast growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
E7337 selectively inhibits FGFR tyrosine kinases, which are frequently dysregulated in various cancers through mutations, amplifications, or translocations. By blocking FGFR-mediated signaling, the drug suppresses tumor cell proliferation and survival in FGFR-dependent malignancies. This mechanism is particularly relevant in cancers with FGFR2 or FGFR3 alterations.
Approved indications
- FGFR-altered solid tumors (in development)
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
- Study Investigating the Effect of E7337 on Tumor Like Lesions in Computed Tomography (CT) of the Liver (PHASE2, PHASE3)
- A Randomized, Open, Parallel, Optimal Injection Rate-Finding Study for E7337 in Dynamic CT of the Liver in Patients With Liver Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E7337 CI brief — competitive landscape report
- E7337 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI